Emulate, Inc.’s Post

🔬 Latest research, published in Nature, unveils a promising strategy against severe flu infections. By targeting necroptosis – a cell death response – a team from Tufts University School of Medicine and Tufts Graduate School of Biomedical Sciences (Degterev Alexei and GSBS student Ioannis Siokas) developed a compound, UH15-38, capable of safeguarding lung tissue without compromising viral restriction. With remarkable results in mice, including preventing flu-related deaths, this compound could optimize flu treatment and possibly combat other respiratory viruses. Collaborating with Fox Chase Cancer Center, University of Houston, and St. Jude Children's Research Hospital, we're advancing towards safer and more effective therapies. 🦠🧬 Learn more about our journey in reshaping infection management: https://ow.ly/gRFL50RlFt8 #FluResearch #Innovation #TuftsMedicine #BiomedicalScience

Ke Y, Liu WN, Her Z, Liu M, Tan SY, Tan YW, Chan XY, Fan Y, Huang EK, Chen H, Chang KTE, Chan JKY, Chu JJH, Chen Q#. Enterovirus-A71 Infection Activates Human Immune Responses and Induces Pathological Changes in Humanized Mice. Journal of Virology January 17, 2019. DOI: 10.1128/JVI.01066-18. Similar to patients with EV-A71, infected humanised mouse model displayed limb weakness. Histopathological examination reviewed the presence of vacuolation, meningomyelitis in the brain stem and spinal cord, and high viral loads. EV-A71-specific human T cell responses were detected and activated human CD4 and CD8 T cells were upregulated after infection. Severe proinflammatory cytokines, such as human gamma interferon (IFN-), interleukin-8 (IL-8), and IL-17A, was elevated in the EV-A71-infected humanized mice. In conclusion, humanised mouse model can provide insights into the human immune responses and pathogenesis of EV-A71 infection, which may be used as a platform for the evaluation of anti-EV-A71 drug candidates. Read the article here: https://lnkd.in/dXfN-h2s #infectiousdiseases

Join us for a free webinar session with BIOQUAL, Inc. Vice President Dr. Swagata Kar and Taconic scientist Dr. Mayara Grizotte-Lake on January 11th: https://bit.ly/48KP0xt 👉 Understand the SARS-CoV-2 infection timeline and clinical disease manifestation in the hACE2 AC70 Mouse, for several SARS-CoV-2 variants 👉 Uncover the value of using wild type viral isolates rather than mouse-adapted viruses for COVID-19 studies 👉 Get insight into key considerations for SARS-CoV-2 study design, including biosafety and how endpoint selection impacts group size

Dr. Kar has served as a principal investigator on more than 200 #COVID-19 related projects over the past three years. Join us for this free webinar to get expert insight on SARS-CoV-2 study design, including biosafety and the impact of endpoint selection: https://bit.ly/3GSR4Y7 👉 Understand the SARS-CoV-2 infection timeline and clinical disease manifestation in the hACE2 AC70 Mouse 👉 Uncover the value of using wild type viral isolates rather than mouse-adapted viruses for COVID-19 studies 👉 Get insight into key considerations for SARS-CoV-2 study design, including biosafety and the impact of endpoint selection

"Impacts of COVID on Long-Term Health" The COVID-19 pandemic has prompted a shift in our scientific focus toward understanding its infectivity and pathogenesis (the process by which an infection leads to disease). However, enigmatic questions persist in individuals harbouring the COVID-19 spike protein during post-infection recovery, which needs further investigation. Barnabe Assogba will share his ongoing research on the potential long-term health effects of COVID-19 “non-infectious aspects.” A fascinating study aims to shed light on the possible influence of the viral glycoprotein on the development of angiosarcoma, a rare yet very aggressive cancer. Part of this investigation involves using siRNA or CRISPR techniques, which are scheduled to be implemented in 2024. Barnabe will explain these techniques. The results will offer substantial potential to enhance future pandemic preparedness and alleviate the strain on the global healthcare system. The session will provide insights and updates from cellular, molecular biology and virology. Dr. Barnabe Assogba has a PhD in Molecular Biology and Virology and is a Biology instructor at KPU. He also mentors undergraduate, master’s, and doctoral students from underrepresented backgrounds. Monday, April 22, 2024 2:00 - 3:30 PM Online event Course fee: $15 Presenter: Barnabe Assogba Facilitator: Jean Garnett For more information, please visit: https://lnkd.in/gTCmGA45

We are pleased to announce that Dr. Quentin Riller officially received the ASPIRE Award 2024 from Prof. Alain Fischer at the European Society for Immunodeficiencies (ESID) 2024 Congress in Marseille. Dr. Riller, a distinguished investigator from the Institut Imagine & Université Paris Cité , was honored for his groundbreaking project titled “Enteric virus-associated hepatitis in patients with a defective antibody response (EVAHDAR) as a new immunopathological condition.” This innovative research aims to unravel the complexities of this liver disease in patients with antibody deficiencies, establishing a crucial link with chronic enteric virus infection. Dr. Riller’s work paves the way for future treatments and offers new insights into primary and secondary immunodeficiency diseases. Founded in 2021, the ASPIRE Award was established to identify and support innovative research projects that offer a greater insight into primary and secondary immunodeficiency diseases. Applications for the ASPIRE Award 2025 will be accepted from November 1st, 2024 👉 https://lnkd.in/dCbsHya #GrifolsScientificAwards #immunology #ESID2024

Scientists from the University of Maryland School of Medicine and JCVI have begun to unwind the role of an "accessory protein" called ORF8 in the SARS-CoV-2 virus. While it isn't needed for the virus to be viable, in mouse models its absence impacted the severity of Covid-19 and inflammatory response. Mice that lacked ORF8 lost more weight and had more macrophages invade their lungs. Similar results were obtained in mice infected with viruses that contained mutations in ORF8 across variants of concern. Future work will focus on defining the role ORF8 plays in viral replication and pathogenesis.   https://lnkd.in/e_K-9Qvh

Long COVID encompasses symptoms persisting or emerging post-initial COVID-19 infection, enduring for weeks, months, or even years. A recent study on High-throughput proteomics on a cohort, including healthy individuals and COVID-19 survivors, highlighted persistent complement-mediated immunopathology associated with thromboinflammation, tissue injury, and increased monocyte-platelet aggregates in Long COVID patients. The immune response to SARS-CoV-2 involves robust activation of innate and adaptive systems, featuring interferons and IgG3 antibodies, protective against Long COVID and ME/CFS. Acute SARS-CoV-2 infection induces inflammation, complement activation, hypercoagulation, and vascular damage. These findings propose potential biomarkers and therapeutic targets. More information DOI: 10.1126/science.adg7942 DOI: 10.1126/science.adn1077 #longCOVID #SARS-CoV-2 #complementactivation #Minnebio #ProteinCommunity2023

A newly identified class of the human immune system’s T cells may kill other T cells, helping wind down attacks on infections and suppressing autoimmune conditions. A key question is why the immune system needs another type of suppressive T cell when it already has T regs. But Tregs are generalists that inhibit a variety of immune cells without killing them. Davis posits that the KIR-positive CD8 cells target particular T cells that switch on during an assault by a pathogen. Although these freshly activated T cells help clear the invaders, they can also attack healthy tissues. The KIR subclass serves as a “SWAT team” to kill off these potentially ruinous T cells once an infection is quelled, Davis proposes. https://lnkd.in/drUxFNq4

https://lnkd.in/dcV6snwq ⚫️ Adjunctive N-Acetylcysteine and Lung Function in Pulmonary Tuberculosis Many patients with cured tuberculosis have permanent lung injury. This trial tested whether N-acetylcysteine (NAC) had beneficial antimicrobial effects and an impact on posttreatment lung function. A total of 140 adults with moderate or far-advanced tuberculosis were assigned 1:1 to standard therapy with or without oral NAC. Although glutathione levels increased with NAC treatment, thus showing biologic activity, there was no impact on microbiologic cure. In a secondary analysis, NAC-treated patients had improved recovery of lung function. @The_NEJM